Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — November 2022

Genmab — November 2022

Planlagt Fastgjort Låst Flyttet Genmab
1.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • BulderB Offline
    BulderB Offline
    Bulder
    wrote on sidst redigeret af
    #168

    Men det betyder så at epco ansøgningen er i god tid inden nytår.

    1 Reply Last reply
    0
    • G Offline
      G Offline
      gentogen
      wrote on sidst redigeret af
      #169

      The timelines for NMEs and BLAs that fall under PDUFA V’s “Program”
      Review Model are 10-months for standard applications and 6-months for priority reviews from the 60-day filing date (or 12 months
      and 8 months respectively from the date of submission of the application).

      1 Reply Last reply
      0
      • G Offline
        G Offline
        gentogen
        wrote on sidst redigeret af
        #170

        Alle detaljer findes her: https://www.fda.gov/media/78941/download

        1 Reply Last reply
        0
        • K Offline
          K Offline
          kkjoel
          wrote on sidst redigeret af
          #171

          Hvordan kan det egentlig være at GEN får den store klump penge (nævnt forleden i opjusterings PM'en) ved accept af ansøgningen og ikke ved selve
          godkendelsen? (eller måske de bare får en endnu større klump ved godkendelsen...?!)

          1 Reply Last reply
          0
          • K Offline
            K Offline
            kkjoel
            wrote on sidst redigeret af
            #172

            (@Duoblo - Nej er på Nørrebro.. men har siden 80'erne holdt meget af "Humus med det hele".. senere kom Shawarma-kødet så bare med.)

            1 Reply Last reply
            0
            • Legolas23L Offline
              Legolas23L Offline
              Legolas23
              wrote on sidst redigeret af
              #173

              Kender vi størrelsen af milestone for epco godkendelse?

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #174

                Det har også undret mig at de får Milestone ved acceptance. Men Andrew Carlsen bekræftede jo ved sidste q&a, at det gør de. Om de så får igen ved godkendelse må tiden vise. Hvad angår størrelsen, skrev de forleden i meddelelsen, at den var signifikant. Det er hvad vi ved - så vidt jeg ved.

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bibob
                  wrote on sidst redigeret af
                  #175

                  GSK’s Blenrep fejlede endemål i MM. https://www.reuters.com/business/healthcare-pharmaceuticals/gsks-blood-cancer-drug-fails-main-goal-superiority-trial-2022-11-07/

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #176

                    ha, you beat my by a second 😉

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #177

                      it looks like that one isn't going to give a lot of competition...

                      1 Reply Last reply
                      0
                      • B Offline
                        B Offline
                        bibob
                        wrote on sidst redigeret af
                        #178

                        EL. 😄

                        1 Reply Last reply
                        0
                        • B Offline
                          B Offline
                          bibob
                          wrote on sidst redigeret af
                          #179

                          Yes one more out. 😉

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #180

                            small mention of epcoritamab in the EMEA CHMP agenda for this week, under B.6.1. Start of procedure for New Applications: https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-7-10-november-2022_en.pdf

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #181

                              also talquetamab, under 8. Pre-submission issues - on the request for accelerated
                              assessment.

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #182

                                BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update https://investors.biontech.de/news-releases/news-release-details/biontech-announces-third-quarter-2022-financial-results-and - Presentation - https://investors.biontech.de/static-files/49e8b81b-bc33-4d65-85ea-c935610dd6b2

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #183

                                  Safety and preliminary efficacy data of BNT312 combination therapy in patients with advanced solid tumors are planned to be presented at the ESMO-Immuno-Oncology annual congress in December 2022. =GEN1042

                                  1 Reply Last reply
                                  0
                                  • D Offline
                                    D Offline
                                    deleted-user
                                    wrote on sidst redigeret af
                                    #184

                                    Genmab sammen med Bava, har ingen omsætning i dag, så det er nok Hr. og Fru. Jensen der styrer markedet med de små handler.

                                    1 Reply Last reply
                                    0
                                    • BulderB Offline
                                      BulderB Offline
                                      Bulder
                                      wrote on sidst redigeret af
                                      #185

                                      Esmo abstract Dec 1. At 00.05 https://www.esmo.org/meeting-calendar/esmo-immuno-oncology-congress-2022/abstract

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #186

                                        Link Preview Image
                                        ESMO Immuno-Oncology Congress 2022: Abstracts | ESMO

                                        favicon

                                        (www.esmo.org)

                                        1 Reply Last reply
                                        0
                                        • BulderB Offline
                                          BulderB Offline
                                          Bulder
                                          wrote on sidst redigeret af
                                          #187

                                          Bliver spændende

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper